GB872146A - Emzymic composition - Google Patents
Emzymic compositionInfo
- Publication number
- GB872146A GB872146A GB46158A GB46158A GB872146A GB 872146 A GB872146 A GB 872146A GB 46158 A GB46158 A GB 46158A GB 46158 A GB46158 A GB 46158A GB 872146 A GB872146 A GB 872146A
- Authority
- GB
- United Kingdom
- Prior art keywords
- streptokinase
- composition
- salivant
- sorbital
- mannitol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 108010023197 Streptokinase Proteins 0.000 abstract 4
- 229960005202 streptokinase Drugs 0.000 abstract 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 2
- 229930195725 Mannitol Natural products 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- 229920002472 Starch Polymers 0.000 abstract 2
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 abstract 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 229940070765 laurate Drugs 0.000 abstract 2
- 239000000594 mannitol Substances 0.000 abstract 2
- 235000010355 mannitol Nutrition 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- ZQBAKBUEJOMQEX-UHFFFAOYSA-N phenyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract 2
- 239000008107 starch Substances 0.000 abstract 2
- 235000019698 starch Nutrition 0.000 abstract 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- JNYAEWCLZODPBN-KVTDHHQDSA-N (2r,3r,4r)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@@H](O)[C@H]1O JNYAEWCLZODPBN-KVTDHHQDSA-N 0.000 abstract 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 abstract 1
- GYYDPBCUIJTIBM-DYOGSRDZSA-N (2r,3s,4s,5r)-2-(hydroxymethyl)-6-[[(4r,5s)-4-hydroxy-3-methyl-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-methoxyoxane-3,5-diol Chemical compound O[C@@H]1[C@@H](OC)[C@@H](O)[C@@H](CO)OC1OC1[C@H]2OCC1OC(C)[C@H]2O GYYDPBCUIJTIBM-DYOGSRDZSA-N 0.000 abstract 1
- 229920001817 Agar Polymers 0.000 abstract 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
- 241000416162 Astragalus gummifer Species 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 abstract 1
- 241000283690 Bos taurus Species 0.000 abstract 1
- 241000167854 Bourreria succulenta Species 0.000 abstract 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 abstract 1
- 229920001353 Dextrin Polymers 0.000 abstract 1
- 239000004375 Dextrin Substances 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 241000283073 Equus caballus Species 0.000 abstract 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 abstract 1
- 239000001828 Gelatine Substances 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 abstract 1
- 241000282414 Homo sapiens Species 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 241001494479 Pecora Species 0.000 abstract 1
- 229930182555 Penicillin Natural products 0.000 abstract 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
- 229920001800 Shellac Polymers 0.000 abstract 1
- 235000021355 Stearic acid Nutrition 0.000 abstract 1
- 235000015125 Sterculia urens Nutrition 0.000 abstract 1
- 240000001058 Sterculia urens Species 0.000 abstract 1
- 241000187747 Streptomyces Species 0.000 abstract 1
- 241000282898 Sus scrofa Species 0.000 abstract 1
- 241000736873 Tetraclinis articulata Species 0.000 abstract 1
- 229920001615 Tragacanth Polymers 0.000 abstract 1
- KIPLYOUQVMMOHB-MXWBXKMOSA-L [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O Chemical compound [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O KIPLYOUQVMMOHB-MXWBXKMOSA-L 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 239000008272 agar Substances 0.000 abstract 1
- 235000010419 agar Nutrition 0.000 abstract 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 abstract 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 abstract 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 abstract 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 abstract 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 abstract 1
- 159000000007 calcium salts Chemical class 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 239000001913 cellulose Substances 0.000 abstract 1
- 229920002678 cellulose Polymers 0.000 abstract 1
- 229960000541 cetyl alcohol Drugs 0.000 abstract 1
- 235000019693 cherries Nutrition 0.000 abstract 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 abstract 1
- 229940097572 chloromycetin Drugs 0.000 abstract 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 abstract 1
- 229960004475 chlortetracycline Drugs 0.000 abstract 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 abstract 1
- 235000019365 chlortetracycline Nutrition 0.000 abstract 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 abstract 1
- 235000019425 dextrin Nutrition 0.000 abstract 1
- 239000008121 dextrose Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000002702 enteric coating Substances 0.000 abstract 1
- 238000009505 enteric coating Methods 0.000 abstract 1
- 229940088598 enzyme Drugs 0.000 abstract 1
- 239000003248 enzyme activator Substances 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 229960002737 fructose Drugs 0.000 abstract 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 abstract 1
- 229930182830 galactose Natural products 0.000 abstract 1
- 229920000159 gelatin Polymers 0.000 abstract 1
- 239000007903 gelatin capsule Substances 0.000 abstract 1
- 235000019322 gelatine Nutrition 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 abstract 1
- 229960000367 inositol Drugs 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 239000001095 magnesium carbonate Substances 0.000 abstract 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 abstract 1
- 239000000347 magnesium hydroxide Substances 0.000 abstract 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 abstract 1
- 239000000395 magnesium oxide Substances 0.000 abstract 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 abstract 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 abstract 1
- 239000013521 mastic Substances 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 abstract 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 abstract 1
- 229940049954 penicillin Drugs 0.000 abstract 1
- 229960000969 phenyl salicylate Drugs 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 210000005059 placental tissue Anatomy 0.000 abstract 1
- 239000011591 potassium Substances 0.000 abstract 1
- 229910052700 potassium Inorganic materials 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 abstract 1
- 229940081974 saccharin Drugs 0.000 abstract 1
- 235000019204 saccharin Nutrition 0.000 abstract 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 abstract 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 abstract 1
- 239000004208 shellac Substances 0.000 abstract 1
- 229940113147 shellac Drugs 0.000 abstract 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 abstract 1
- 235000013874 shellac Nutrition 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000008117 stearic acid Substances 0.000 abstract 1
- 229960005322 streptomycin Drugs 0.000 abstract 1
- 229940063650 terramycin Drugs 0.000 abstract 1
- 239000000196 tragacanth Substances 0.000 abstract 1
- 235000010487 tragacanth Nutrition 0.000 abstract 1
- 229940116362 tragacanth Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- A61K38/166—Streptokinase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
A composition of matter in dry form suitable for oral administration contains streptokinase and a pharmaceutically acceptable carrier which may be an excipient, a water-soluble solid polyethylene glycol, a salivant or a mixture thereof. The composition, which may take the form of a tablet or a powder enclosed in a capsule, e.g. a gelatin capsule, which may be enterically coated, may contain as an additional ingredient, a dried animal substance selected from dried placental tissue, muscle tissue, ammiotic fluid or plasma, e.g. human, bovine, sheep, horse or pig plasma. The streptokinase may be present in amount from 5000 to 150,000 units and the dried animal substance in an amount from 10 to 75 mgm. per dosage unit. The polyethylene glycol may have a molecular weight of 1500 or 4000. The salivant may be saccharin or a sodium, potassium or calcium salt of cyclohexyl sulphamic acid, which may be present from 1/128 to 1/32 grain per dosage unit. Suitable excipients are starch, soluble starch, lactose, magnesium oxide, carbonate or hydroxide, aluminium hydroxide, galactose, dextrin, dextrose, karaya, tragacanth, agar, indian, cherry and plum gum, gum agar, sorbital, sorbose, sorbital laurate, sorbitan, mannitol, mannitol laurate, mannitan, dulcitol, levulose, inositol, arabinose, methyl p cellulose, gelatine and sodium chloride. The enteric coating may be of salol, shellac, tolu, stearic acid, mastic, sandarac and cetyl alcohol. The composition may also contain insulin, and antibiotics, e.g. penicillin, streptomycin, aureomycin, "Chloromycetin" and "Terramycin" (Registered Trade Marks). The term "streptokinase" includes kinases enzyme activators which are produced by bacteria other than streptomyces bacteria, capable of the same enzyme activation as streptokinase.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB46158A GB872146A (en) | 1958-01-06 | 1958-01-06 | Emzymic composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB46158A GB872146A (en) | 1958-01-06 | 1958-01-06 | Emzymic composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB872146A true GB872146A (en) | 1961-07-05 |
Family
ID=9704757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB46158A Expired GB872146A (en) | 1958-01-06 | 1958-01-06 | Emzymic composition |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB872146A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1938392A1 (en) * | 1968-10-31 | 1970-05-06 | Rech S Ind S O R I Soc D | Process for the production of an enzyme-containing, sprayable medicinal product |
| FR2483234A2 (en) * | 1980-05-29 | 1981-12-04 | Fabre Sa Pierre | OPHTHALMIC COMPOSITION CONTAINING A PLASMINOGEN ACTIVATOR |
| US5436011A (en) * | 1993-04-16 | 1995-07-25 | Bristol-Myers Squibb Company | Solid pharmaceutical dosage form and a method for reducing abrasion |
| WO2004004754A1 (en) * | 2002-07-09 | 2004-01-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel medicament combinations based on magnesium salts and fibrinolytics |
-
1958
- 1958-01-06 GB GB46158A patent/GB872146A/en not_active Expired
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1938392A1 (en) * | 1968-10-31 | 1970-05-06 | Rech S Ind S O R I Soc D | Process for the production of an enzyme-containing, sprayable medicinal product |
| FR2483234A2 (en) * | 1980-05-29 | 1981-12-04 | Fabre Sa Pierre | OPHTHALMIC COMPOSITION CONTAINING A PLASMINOGEN ACTIVATOR |
| EP0041449A1 (en) * | 1980-05-29 | 1981-12-09 | Pierre Fabre S.A. | Application of an ophthalmic composition containing a plasminogen activator to contact lenses cleaning |
| US5436011A (en) * | 1993-04-16 | 1995-07-25 | Bristol-Myers Squibb Company | Solid pharmaceutical dosage form and a method for reducing abrasion |
| WO2004004754A1 (en) * | 2002-07-09 | 2004-01-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel medicament combinations based on magnesium salts and fibrinolytics |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU96102154A (en) | NEW PHARMACEUTICAL COMPOSITION, METHOD FOR ITS PRODUCTION, METHOD FOR TREATING DISEASES USING THE COMPOSITION | |
| JPS643193A (en) | Cell and tissue reparative agent | |
| US2798024A (en) | Composite enteric tablet of erythromycin and sulfonamides | |
| GB872146A (en) | Emzymic composition | |
| EG19302A (en) | Compound with gastric acid inhibitory effect and process for its preparation | |
| US3696188A (en) | Laminated tablets | |
| GB1422193A (en) | Pharmaceutical compositions | |
| NO873273D0 (en) | MULTIPLE-GRAN TABLE FOR DELIVERING AN ACTIVE INGREDIENT OVER TIME. | |
| FR2500303B1 (en) | ||
| US3019167A (en) | Method of administering streptokinase systemically | |
| USRE28636E (en) | Antibacterial composition containing 5-methyl-3-sulfanilamidoisoxazole and trimethoxybenyl pyrimidine | |
| GB908282A (en) | Coated pharmaceutical granules and tablets thereof | |
| NO156900B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 1,3,4-OCSADIAZOLYLPHENOL DERIVATIVES. | |
| GB817329A (en) | Therapeutic compositions containing a protease | |
| DE3062300D1 (en) | Piperidine derivatives of 4,5-dialkyl-3-hydroxy-pyrrole-2-carboxylic acid esters, their preparation and pharmaceutical compositions containing them | |
| MY101266A (en) | Pharmaceutical formulations | |
| GB1118606A (en) | Compositions for the treatment of haemorrhoids | |
| GB1033843A (en) | Pharmaceutical composition for treating thermatoid arthritis | |
| GB1056116A (en) | Enzyme-containing anti-asthmatic preparations | |
| FR2077913A1 (en) | Tablets contg gelatine capsules - for administration of liquid medicaments | |
| US3737546A (en) | Use of ipronidazole in combatting swine dysentery | |
| US2726984A (en) | Composition for combatting amoebiasis comprising 1:2-bis(4'-arsono-phenylamino)-ethane | |
| GB1375806A (en) | ||
| GB878432A (en) | Therapeutic compositions containing sulphonamides | |
| ES8106895A1 (en) | Amino derivatives of 5-(2-hydroxystyryl) isoxazole, methods for their preparation and therapeutical compositions containing them. |